Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

87 results about "11β-hydroxysteroid dehydrogenase type 1" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

11β-hydroxysteroid dehydrogenase type 1, or 'cortisone reductase' is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues, HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. It is inhibited by carbenoxolone, a drug typically used in the treatment of peptic ulcers. Moreover, 18alpha-glycyrrhizic acid from the root of Glycyrrhiza glabra was discovered as an inhibitor A study from 2014 found that Epigallocatechin gallate from Green tea can also potently inhibit this reaction, which might partly explain the anti-stress properties of Green tea consumption. The protein encoded by this gene is a microsomal enzyme that catalyzes the conversion of the stress hormone cortisol to the inactive metabolite cortisone. In addition, the encoded protein can catalyze the reverse reaction, the conversion of cortisone to cortisol. Too much cortisol can lead to central obesity, and a particular variation in this gene has been associated with obesity and insulin resistance in children.

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

InactiveUS20060094699A1Reduce adverse side effectsUndesirable side-effectBiocideAnimal repellants11beta hydroxysteroid dehydrogenaseSide effect

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

Owner:HIGH POINT PHARMA

Pharmaceutical use of substituted amides

InactiveUS20060111366A1BiocideOrganic chemistryMedical disorderGlucocorticoid

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and / or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Owner:HIGH POINT PHARMA

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

InactiveUS20050277647A1Organic active ingredientsOrganic chemistryDiseaseInsulin dependent

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Owner:ABBVIE INC

11beta-hydroxysteroid dehydrogenase type 1 active compounds

InactiveUS20060089349A1BiocideOrganic chemistryDisease11beta hydroxysteroid dehydrogenase

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

11beta-hydroxysteroid dehydrogenase type 1 active compounds

11beta-hydroxysteroid dehydrogenase type 1 active compounds

11beta-hydroxysteroid dehydrogenase type 1 active compounds

Owner:HIGH POINT PHARMA

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

InactiveUS7501405B2Reduce development riskBiocideMetabolism disorderHypertension medicationsDyslipidemia

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

Owner:VTV THERAPEUTICS LLC

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

InactiveUS20110124635A1Antibacterial agentsOrganic active ingredientsCortisoneHydrocortisone

This invention relates to novel compounds of the Formula (I), (II), 1u1-20, Iv1-20, Iv1-20, Iw1-20, Ix1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 1β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Owner:VITAE PHARMA INC

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

ActiveUS20110021512A1Organic active ingredientsOrganic chemistryDiseaseCortisone

This invention relates to novel compounds of the Formula Ik, Im¹, Im², Im⁵, In¹, In², In⁵, lo¹, lo², lo⁵, Ip¹, Ip³, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Owner:BOEHRINGER INGELHEIM INT GMBH

Amide Derivatives and Pharmaceutical Use Thereof

InactiveUS20090264414A1BiocideSenses disorderGlucocorticoidHydroxysteroid

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and / or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Amide Derivatives and Pharmaceutical Use Thereof

Amide Derivatives and Pharmaceutical Use Thereof

Amide Derivatives and Pharmaceutical Use Thereof

Owner:HIGH POINT PHARMA

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

ActiveUS8138178B2Organic active ingredientsOrganic chemistryEnantiomerMedicine

Disclosed is a compound represented by Formula (Im1)or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof and methods of inhibiting 11β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formulas (Im1), or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Owner:BOEHRINGER INGELHEIM INT GMBH

Urea derivatives of tropane, their preparation and their therapeutic application

InactiveUS20090170894A1BiocideSenses disorderUrea derivativesTropane

The present invention is related to a compound of formula (I)wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1).

Urea derivatives of tropane, their preparation and their therapeutic application

Urea derivatives of tropane, their preparation and their therapeutic application

Urea derivatives of tropane, their preparation and their therapeutic application

Owner:SANOFI SA

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

ActiveUS20110263584A1Organic active ingredientsSenses disorderDiseaseCortisone

This invention relates to novel compounds of the Formula I, Ik, Iq^1-21, Ir^1-21, Is^1-21, It^1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Owner:VITAE PHARMA INC +1

Pharmaceutical use of substituted 1,2,4-triazoles

InactiveUS20060100235A1BiocideOrganic chemistryDiseaseMedical disorder

The use of substituted 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of substituted 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted 1,2,4-triazoles

Pharmaceutical use of substituted 1,2,4-triazoles

Pharmaceutical use of substituted 1,2,4-triazoles

Owner:NOVO NORDISK AS

Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy

InactiveUS20090264412A1Undesirable side-effectBiocideAnimal repellantsDisease11beta hydroxysteroid dehydrogenase

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy

Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy

Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy

Owner:HIGH POINT PHARMA

Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines

InactiveUS20070270408A1BiocideMetabolism disorderDiseaseMedical disorder

The use of substituted pyrazolo[1,5-a]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions are described. Also a novel class of substituted pyrazolo[1,5-a]pyrimidines their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines

Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines

Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines

Owner:HIGH POINT PHARMA

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

ActiveUS20120178746A1Organic active ingredientsOrganic chemistryDiseaseCortisone

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Owner:BOEHRINGER INGELHEIM INT GMBH +1

Pharmaceutical use of fused 1,2,4-triazoles

InactiveUS7358238B2BiocideSenses disorderGlucocorticoidMedicine

The use of fused 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and / or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of fused 1,2,4-triazoles

Pharmaceutical use of fused 1,2,4-triazoles

Pharmaceutical use of fused 1,2,4-triazoles

Owner:HIGH POINT PHARMA

Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

InactiveUS20110112062A1BiocideSenses disorderDiseaseCarbamate

This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 V1, V1a, VIb, VII, Vi1a, VIIb, VIII, V111a, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1

Owner:VITAE PHARMA INC

Pharmaceutical use of substituted amides

InactiveUS20090124598A1BiocideSenses disorderGlucocorticoidDepressant

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Owner:HIGH POINT PHARMA

Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1

InactiveUS20110112082A1Inhibitory activityAntibacterial agentsOrganic active ingredientsDiseaseMammal

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(If), (Ig), (Ih), (Ii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Owner:VITAE PHARMA INC

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

ActiveUS7217838B2Improve throughputLimit deliveryOrganic active ingredientsOrganic chemistryDiseaseInsulin dependent

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Owner:ABBVIE INC

Pharmaceutical use of fused 1,2,4-triazoles

InactiveUS20060106008A1BiocideSenses disorderMedical disorderMedicine

The use of fused 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of fused 1,2,4-triazoles

Pharmaceutical use of fused 1,2,4-triazoles

Pharmaceutical use of fused 1,2,4-triazoles

Owner:HIGH POINT PHARMA

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

ActiveUS20120172357A1Organic active ingredientsSenses disorderDiseaseCortisone

This invention relates to novel compounds of the Formula (I), dependent compounds of Formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (III), (III-A), (III-B), (III-C), (IV), (IV-A), (IV-B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

Owner:BOEHRINGER INGELHEIM INT GMBH

Adamantane derivatives for the treatment of the metabolic syndrome

InactiveUS20100168083A1BiocideOrganic chemistryDiseaseBiochemistry

Novel substituted adamantane based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

Adamantane derivatives for the treatment of the metabolic syndrome

Adamantane derivatives for the treatment of the metabolic syndrome

Adamantane derivatives for the treatment of the metabolic syndrome

Owner:HIGH POINT PHARMA

11beta-hsd1 active compounds

InactiveUS20100056600A1BiocideOrganic chemistryDiseaseMetabolic syndrome

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

11beta-hsd1 active compounds

11beta-hsd1 active compounds

11beta-hsd1 active compounds

Owner:HIGH POINT PHARMA

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

InactiveUS20110003856A1Decreased intracellular concentrationImpaired glucose toleranceBiocideSenses disorderDisease11-beta-Hydroxysteroid Dehydrogenases

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

Owner:HIGH POINT PHARMA

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

InactiveUS20110003852A1BiocideOrganic chemistryDisease11-beta-Hydroxysteroid Dehydrogenases

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

Owner:HIGH POINT PHARMA

Pharmaceutical use of substituted amides

InactiveUS20080108598A1BiocideOrganic chemistryDiseaseMedical disorder

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and / or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Pharmaceutical use of substituted amides

Owner:HIGH POINT PHARMA

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

ActiveUS20110039853A1Decreased intracellular concentrationImpaired glucose toleranceBiocideNervous disorderDisease11-beta-Hydroxysteroid Dehydrogenases

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

Owner:VTV THERAPEUTICS LLC

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

ActiveUS20120108578A1Antibacterial agentsOrganic active ingredientsDiseaseCortisone

This invention relates to novel compounds of the Formula (I), (Ia^1-10), (Ib^1-10), (Ic^1-10), (Id^1-7), (Ie^1-5) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

Owner:BOEHRINGER INGELHEIM INT GMBH +1

Pharmaceutical use of substituted piperidine carboxamides

InactiveUS20090306048A1BiocideSenses disorderDiseaseMetabolic syndrome

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

Pharmaceutical use of substituted piperidine carboxamides

Pharmaceutical use of substituted piperidine carboxamides

Pharmaceutical use of substituted piperidine carboxamides

Owner:HIGH POINT PHARMA

Popular searches

Agonist Combination therapy Glucocorticoid Receptor Agonists Disease cause 11β-hydroxysteroid dehydrogenase type 1 Hormone Inflammation Disease injury Cancer Hydroxysteroid dehydrogenase

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap